SLC6A2 and paraganglioma: In particular, therapies using 177Lu-DOTATATE and 131I-MIBG have been employed in cases of aggressive or unresectable paragangliomas due to their ability to selectively target somatostatin receptors and norepinephrine transporters, respectively [35].